Compass, Inc. announced a Q1 2026 net income of $22 million and adjusted EBITDA of $61 million, driven by strong revenue growth and cost synergies following its merger with Anywhere. The company achieved over $250 million in net cost synergies within 82 days post-merger and raised its 2026 synergy targets, expecting $200 million in realized cost synergies and $300 million in actioned synergies. Pro forma brokerage transactions and gross transaction value grew 2.6% and 7.3% year-over-year, outperforming the market. Compass projects continued revenue growth and positive free cash flow for 2026, focusing on operational efficiency and debt reduction.
Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, ...
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
Audiera (BEAT) surged 16.18% to $2.61, leading altcoin gains driven by its decentralized music streaming platform and innovative artist compensation model. Other notable gainers include MemeCore, Lighter, and DeXe, reflecting growing interest in NFTs...
Kahn Swick & Foti, LLC is investigating Inspire Medical Systems following the company's announcement of delays in launching its Inspire V device and a significant cut in 2025 earnings guidance by over 80%. The delays were due to undisclosed issues su...
